News | May 21, 2018

Intramural Needle Ablation Effective for Refractory Ventricular Arrhythmias

Intramural Needle Ablation Effective for Refractory Ventricular Arrhythmias. #HRS2018

May 21, 2018 — The available electrophysiology catheter ablation technologies are not designed for use in the ventricular anatomy, so a new needle ablation catheter from Biosense Webster was tested in a study to assessed the safety.[1] The six-month data from the study was presented at Heart Rhythm 2018, the Heart Rhythm Society’s 39th Annual Scientific Sessions.

All of the patients had failed using a standard approach and then using the needle we were able to get rid of their tachycardia

All 31 patients included in the trial failed standard ablation and medical therapy. However, the needle-based system was able to eliminate their tachycardia. 

Intramural origin is an important cause of ventricular arrhythmia (VA) ablation failure that we are attempting to address with an irrigated needle ablation catheter. This study assessed the safety and six-month outcome of irrigated needle ablation in patients with sustained monomorphic ventricular tachycardia (VT) and structural heart disease or nonsustained ventricular arrhythmia and left ventricular (LV) dysfunction not responsive to antiarrhythmic drugs and standard catheter ablation. 

Patients were enrolled at three centers. At putative target sites selected based on endocardial mapping, the 27 gauge needle was deployed up to 10 mm into the myocardium for recording and pace mapping. Then irrigated with contrast/saline for radiofrequency (RF) ablation with current titrated to a maximum needle temperature of 60 degrees Centigrade.

Irrigated needle ablation was performed in 31 patients at the three centers. Most patients had nonischemic heart disease (NICM) with sustained monomorphic VT (table). A median of 15 RF needle applications per patient were delivered to selected RV/LV septum and free wall sites.

 

Links to all the Heart Rhythm 2018 Late-breaking Studies

 

Reference:

1. Intramural Needle Ablation for the Treatment of Refractory Ventricular Arrhythmias. ClinicalTrials.gov Identifier: NCT03204981. https://clinicaltrials.gov/ct2/show/NCT03204981

 

#HRS2018 #HRS18

Related Content

FDA Approves Biosense Webster's Tag-Index Guided Ablation Software
Technology | Ablation Systems | October 09, 2018
Biosense Webster Inc. recently received approval from the U.S. Food and Drug Administration (FDA) for its Visitag...
Medtronic Cryoballoon Improves Quality of Life, Reduces Systems of Persistent Atrial Fibrillation
News | Ablation Systems | August 28, 2018
Medtronic plc announced new findings from the CRYO4PERSISTENT AF clinical trial demonstrating improved quality of life...
Thermedical Announces FDA IDE Approval for Clinical Study of Durablate Catheter
News | Ablation Systems | August 02, 2018
Thermedical announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device...
Boston Scientific to Acquire Cryterion Medical Inc.
News | Ablation Systems | July 13, 2018
Boston Scientific Corp. recently announced a definitive agreement to acquire Cryterion Medical Inc., a privately-held...
Treating AFib With Ablation Reduces Mortality and Stroke
News | Ablation Systems | July 05, 2018
Using catheter-based ablation instead of medications alone reduces the risks of death and stroke in patients with the...
LuxCath Showcases OmniView Light-Guided Ablation Catheter at HRS 2018
News | Ablation Systems | May 22, 2018
LuxCath LLC showcased the next generation of its proprietary OmniView light-guided catheter ablation system at the 2018...
The Kardium Globe combined mapping and ablation catheter. The device has a distal multi-electrode array consisting of 16 ribs with 122 gold-plated electrodes. Ablation can be done with up to 24 electrodes simultaneously.  #HRS2018

The Kardium Globe combined mapping and ablation catheter. The device has a distal multi-electrode array consisting of 16 ribs with 122 gold-plated electrodes. Ablation can be done with up to 24 electrodes simultaneously. 

News | Ablation Systems | May 21, 2018
May 21, 2018 — Complete pulmonary vein isolation (PVI) was achieved in more than 99 percent of patients in a first-in
CardioFocus Announces Successful Live Case Featuring HeartLight X3 System
News | Ablation Systems | May 17, 2018
Medical device manufacturer CardioFocus Inc. announced a successful live case featuring its HeartLight X3 System during...
Imricor MRI-Guided Cardiac Ablation Study Results to Be Presented at HRS 2018
News | Ablation Systems | May 10, 2018
Results from the clinical study to evaluate Imricor’s Vision-MR Ablation Catheter for the treatment of atrial flutter...
Biosense Webster Launches Carto Vizigo Bi-Directional Guidance Sheath
Technology | Ablation Systems | May 08, 2018
Biosense Webster Inc. announced its Carto Vizigo Bi-directional Guiding Sheath is now available in the United States....
Overlay Init